Privium Fund Management B.V. Takes $909,000 Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Privium Fund Management B.V. purchased a new stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) in the fourth quarter, HoldingsChannel reports. The firm purchased 138,115 shares of the company’s stock, valued at approximately $909,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LXEO. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter valued at approximately $46,000. BNP Paribas Financial Markets raised its position in shares of Lexeo Therapeutics by 184.2% in the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after buying an additional 3,591 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Lexeo Therapeutics in the fourth quarter valued at approximately $72,000. JPMorgan Chase & Co. raised its position in shares of Lexeo Therapeutics by 135.6% in the third quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock valued at $93,000 after buying an additional 5,915 shares in the last quarter. Finally, MetLife Investment Management LLC raised its position in shares of Lexeo Therapeutics by 121.5% in the third quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock valued at $129,000 after buying an additional 7,803 shares in the last quarter. 60.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Royal Bank of Canada reissued an “outperform” rating and issued a $24.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday, January 21st. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $23.80.

Lexeo Therapeutics Stock Performance

Shares of NASDAQ:LXEO opened at $2.96 on Wednesday. The company’s 50 day simple moving average is $4.42 and its 200 day simple moving average is $6.94. The stock has a market capitalization of $97.88 million, a price-to-earnings ratio of -0.94 and a beta of 3.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. Lexeo Therapeutics, Inc. has a 1 year low of $2.32 and a 1 year high of $19.50.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.